BioCryst Pharma (BCRX) Continues Higher Following Speculation of Ebola Cure

BioCryst (Nasdaq: BCRX) is taking another leg higher today following positive commentary in Forbes.

Specifically, Forbes refers to BioCryst's BCX4430, which could be a cure for the Ebola virus. The author stated, The new drug, BCX4430, works by blocking the reproduction of the virus inside infected cells ... Chemically, it is similar to adenosine, one of the four letters of the genetic code ... But when the virus tries to build new copies of itself using BCX4430 instead of adenosine, the process comes to a grinding halt.

Read the rest of the piece here. Shares of BioCryst are up 7.9 percent.

You May Also Be Interested In

• Deere conference call: 2027 orders up mid-single digits from last year)
• EIA: U.S. natural-gas stockpiles up 16 BCF last week
• Sk Hynix To Pay 60% Of Employee Bonuses In Company Stock, Says Source - Reuters